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Abstract
Background: Rett syndrome (RTT) is a neurodevelopmental disorder most often related to a pathogenic variant in
the X-linked MECP2 gene. Internalizing behaviors appear to be common, but standard methods of diagnosing anxiety
are not readily applied in this population which typically has cognitive impairment and limited expressive language.
This study aims to describe the frequency of anxiety-like behavior and anxiolytic treatments along with associated
clinical features in individuals with RTT.
Methods: Parental reports and medication logs provided data from 1380 females with RTT participating in two iterations of the multicenter U.S. RTT Natural History Study (RNHS) from 2006 to 2019.
Results: Most participants with RTT (77.5%) had at least occasional anxious or nervous behavior. Anxiety was
reported to be the most troublesome concern for 2.6%, and within the top 3 concerns for 10.0%, of participants in the
second iteration. Parents directly reported treatment for anxious or nervous behavior in 16.6% of participants in the
second iteration with most reporting good control of the behavior (71.6%). In the medication logs of both RNHS iterations, the indication of anxiety was listed for a similar number of participants (15% and 14.5%, respectively). Increased
use of anxiolytics and selective serotonin reuptake inhibitors (SSRIs) was related to more frequent anxiety-like behaviors (P < 0.001), older age (P < 0.001), and mild MECP2 variants (P = 0.002).
Conclusion: Anxiety-like behavior is frequent at all ages and is a significant parental concern in RTT. Older individuals
and those with mild MECP2 variants are more likely to be treated with medications. Better diagnosis and treatment of
anxiety in RTT should be a goal of both future studies and clinical care.
Trial registration: NCT00299312 and NCT02738281
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Background
Rett syndrome (RTT; OMIM 312750) is a genetic neurodevelopmental disorder that occurs in approximately 1
in 10,000 females [13]. Intellectual disability and communication and motor deficits occur after a period of regression with recovery or stabilization in early childhood
[2, 11]. While individual presentations can vary greatly,
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diagnostic criteria for RTT include a period of regression plus 4 characteristic neurologic features: partial or
complete loss of acquired hand skills, partial or complete
loss of acquired spoken language, absent or abnormal
gait, and hand stereotypies [22]. If all 4 main criteria are
met, the diagnosis is considered classic (or typical) RTT
while individuals with variant (or atypical) RTT meet at
least 2 of the 4 main criteria plus 5 of 11 supportive criteria. Behavioral difficulties, such as inappropriate fear
and abrupt mood changes, though not included in the
diagnostic criteria, appear to be common and have been
recognized since the early descriptions of the disorder
[1, 3, 8, 19]. The neurologic features of RTT are typically related to a pathogenic variant in the X-linked gene
encoding the methyl-CpG-binding protein 2 (MeCP2),
a transcriptional regulator involved in synaptic development and maintenance of neuronal circuitry [2]. While
genotype-phenotype correlations are limited, a few of the
more than 500 MECP2 pathogenic variants in RTT are
known to correlate with disease severity [14]. Increased
age also correlates with increased disease severity [11,
14].
The US RTT Natural History Study (RNHS) is a longitudinal, observational study of the largest cohort of individuals with the disorder. The data collected included
age, diagnosis (typical vs. atypical), MECP2 variant, and
a variety of specific clinical features, including two scales
of clinical severity. Anxiety-specific assessments and
psychiatric diagnoses were not collected in the RNHS.
However, the first iteration of the RNHS contained medication logs providing information on treated behavioral
disorders (including anxiety) and the second iteration, in
addition to medication logs, collected parent-reported
severity of anxious or nervous behavior, and medication
use and effectiveness for anxiety.
Anxiety is considered an internalizing behavior, along
with depressed mood, obsessive-compulsive behaviors,
and somatic complaints [6, 18, 30]. Although the exact
prevalence of anxiety in RTT is unknown [1, 3, 8, 19],
we previously reported that internalizing behaviors, as
defined by the Mental Health/Well-being (MH) scale
from the Child Health Questionnaire–Parent Form
50 (CHQ-PF50) as feeling lonely, feeling like crying,
acting upset or acting nervous [17], are common and
clinically significant in RTT in the first iteration of the
RNHS. Indeed, scores on the CHQ MH in classic RTT
were comparable to those in individuals with a range of
psychiatric diagnoses and worse than in patients with
epilepsy and in the general population. Internalizing
behaviors were more severe in participants with mild
MECP2 pathogenic variants (R133C, R294X, R306C,
and C-terminal truncations) when compared to participants with either moderate (T158M and other point
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mutations) or severe pathogenic variants (R106W,
R168X, R255X, R270X, early truncations, large deletions, and splice site) [5]. Another study that examined the profiles of anxious behavior in girls with RTT
similarly reported that higher anxiety scores predominantly occurred in children with less severe neurologic
impairment and were associated with a lower quality of
life [3].
Existing diagnostic and assessment tools for anxiety
and other internalizing behaviors are often inappropriate
in RTT because of the cognitive impairment and limited
verbal communication of this population. Further complicating the recognition of anxiety in individuals with
RTT is the common presence of anxiety-like behavior,
such as worsening of hyperventilation and breath holding, in situations that would not be expected to induce
anxiety. Other manifestations of anxiety in RTT may
include inability to relax, inconsolable crying, tenseness,
trembling, screaming episodes, avoidance of eye contact,
and social withdrawal [3, 8, 9, 12, 15, 19–21, 25, 27, 28].
Barnes et al. [3] demonstrated the feasibility of evaluating different subtypes of anxiety behaviors in children
with RTT using the Anxiety, Depression, and Mood Scale
(ADAMS) for individuals with intellectual disability. Nevertheless, of the five ADAMS subscales, only the Social
Avoidance subscale showed the range of psychometric
properties suitable for clinical and research applications
in this population.
In spite of the general impression that anxiety-like
behavior is common in individuals with RTT, no systematic studies of anxiolytics use have been reported in this
population and guidelines for clinical management of
anxiety in RTT do not exist. Selective serotonin reuptake
inhibitors (SSRIs) have been suggested for the treatment
of anxiety and abnormal mood while benzodiazepines
have been recognized as a potential therapy for breathing
irregularities [7]. We conducted an exploratory analysis
of individuals being treated with anxiolytic medication
(e.g., SSRIs); in line with current perspectives on anxiety
in neurodevelopmental disorders, treated individuals had
more severe profiles of internalizing behaviors than their
non-treated counterparts [5].
Given the apparent high frequency of anxiety-like
behaviors in individuals with RTT, the significant
impact anxiety can have on quality of life, the shortage
of appropriate assessment tools for this mostly nonverbal population, and the lack of guidelines on the clinical
management of anxiety in RTT, the goal of this study was
to provide the first large-scale description of anxiety-like
behavior in RTT using data from the RNHS. In this investigation, we characterize individuals with RTT reported
to have anxious behavior or being treated for anxiety to
address the current gap in knowledge.
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Methods
Participants

Participants were recruited through the multicenter
RNHS to provide suitable longitudinal information that
could serve as the foundation for conducting translational research including clinical trials. Assessments were
conducted every 6 to 24 months by clinicians at one of
eight sites in the USA from 2006 to 2015 (first iteration)
and at 1 of 14 sites from 2015 to 2019 (second iteration).
Data from 1380 females with RTT (718 in the first iteration only, 310 in the second iteration only, and 352 in
both iterations) were included (Fig. 1). Medication log
data from the first iteration were compared with parental
report of anxiety-like behavior from the second iteration.
Participants from both iterations allowed confirmation of
parental report accuracy. Only baseline measures from
each iteration were analyzed for this report. All female
participants with a diagnosis of RTT (typical and atypical), regardless of MECP2 pathogenic variant status,
were considered for inclusion in the analyses presented
here. For this analysis, data were excluded from males,
participants with a non-RTT diagnosis, and participants
missing significant baseline data. The RNHS consortium
is part of the Rare Diseases Clinical Research Network
(RDCRN), an initiative of the Office of Rare Diseases
Research, National Center for Advancing Translational
Sciences, National Institutes of Health.
Human studies approval

Parental consent for study conduct and publication of
results was obtained prior to entry into the study for all
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participants. Each participating institution retained institutional review board approval for the implementation of
this study protocol and consent form (ClinicalTrials.gov
identifiers: NCT00299312 and NCT02738281).
Diagnosis

Diagnoses of RTT were based on published diagnostic
guidelines, whether classic (typical), variant (atypical), or
other related phenotypes by a RNHS site Principal Investigator [22].
MECP2 pathogenic variants

MECP2 variants were reported from clinical laboratory
testing. We categorized pathogenic variants as severe
(R106W, R168X, R255X, R270X, early truncations, large
deletions, and splice site), moderate (T158M and other
point mutations), or mild (R133C, R294X, R306C, and
C-terminal truncations) based on prior reports of genotype-phenotype correlations [4, 11, 23, 29]. Participants
with clinical RTT without a MECP2 variant or with variants in exon 1 were excluded from analyses involving
MECP2 severity.
Measures
Clinical severity scale (CSS)

The CSS is a clinician-completed questionnaire that uses
a Likert-type scale to measure clinical features common
in RTT, including age at onset of regression, somatic
and head growth status, motor, communication, and
RTT behaviors/other neurologic symptoms. Each item is

Fig. 1 Rett syndrome natural history study (RNHS) participants selected for analysis (n = 1380). Both = subjects participating in both the first and
second iterations; cohort 1 = subjects only participating in the first iteration; cohort 2 = subjects only participating in the second iteration
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ranked from either 0–4 or 0–5, with higher scores indicating greater clinical severity (range 1–58).
Motor behavioral assessment (MBA)

The MBA is a clinician-completed questionnaire for RTT
that uses a Likert-type scale to score multiple items based
on severity from 0 to 4, with a maximum total score of
148 (first iteration) or 136 (second iteration, with 3 previously low-scoring items removed). The scale includes
measures of behavioral/social assessment, orofacial/
respiratory assessment, and motor assessment/physical
signs. A higher score indicates greater clinical severity.
Anxiolytic and/or SSRI treatment

The first iteration of the RNHS did not include direct
parental assessment of anxiolytics use but the second iteration explicitly asked if the child was prescribed medication for being anxious or nervous. Both
iterations of the RNHS collected comprehensive data
regarding developmental and medical history, including
medication use and indication. Medication logs from
both iterations were reviewed for the indication of “anxiety” entered as either free text or as a SNOMED code,
regardless of the type of medication associated with that
entry. Medication logs were also reviewed for reported
use of any SSRI, regardless of the indication associated
with that entry.
Anxious behavior

The first iteration of the RNHS did not include specific
questions about anxious behavior but the second iteration explicitly asked how frequently the child was anxious
or nervous (with results on a scale of 0–4), whether the
child was medicated for being anxious or nervous and, if
yes, was the behavior well or poorly controlled. Parents
were also asked to choose from a list of common features
of RTT and select the top 3 features that have had the
greatest impact on their child’s quality of life in the past
6 months.
Analytical strategy

Data from the second iteration of the RNHS constituted
the primary source for the analyses, which included frequency of anxious/nervous and other abnormal behaviors, frequency and effectiveness of treatment for anxiety,
drug type used to treat anxiety in RTT, and clinical characteristics of participants. Data from the first iteration
of the RNHS were used as a potential source of convergent evidence for profiles of individuals with RTT
treated pharmacologically for anxiety. Comparisons of
direct report and medication logs for overlapping and
non-overlapping subgroups of the second iteration were
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employed to assess comparability of first and second iteration datasets and accuracy of parental report of anxietylike behavior.
Statistical analyses

Descriptive statistics were used for characterizing most
parameters, with continuous variables described in
terms of means, standard deviations (SD), and ranges
and categorical variables mainly as frequencies. Groups’
age and clinical severity, based on CSS or MBA total
scores, were compared using the Mann-Whitney U or
Kruskal-Wallis tests. Parent-reported frequency of anxious behavior in different groups was compared by Chisquare test or Fisher’s exact test. Frequency of other
parameters and categorical variables, such as race, ethnicity, RTT diagnosis, MECP2 severity, parental report
of anxiolytic use, medication log report of anxiolytic use,
and medication log report of SSRI use, were also analyzed by these tests. Two-sided P values less than 0.05
were considered significant; Bonferroni adjustments
for multiple comparisons were used for analyses where
appropriate. The analyses were performed using SPSS
version 24.
Characteristics of the study population

Figure 1 displays the number of participants across the
years of the first (2006–2015) and second (2015–2019)
iterations of the RNHS, including the number of individuals unique to each study and those participating in
both iterations. Table 1 displays the clinical features of
the participants. Race and ethnicity differ between the
study iterations, though most participants (> 85%) are
White and non-Hispanic. Participants in the second
iteration of the RNHS were older than the first iteration
and displayed higher clinical severity scores, as expected
from earlier studies. Older age was expected in the second iteration given the overlap of participants. Unexpectedly, when overlapping participants were removed from
analysis, on average, participants in the second iteration
were older than participants in the first iteration but had
similar clinical severity. The type of RTT diagnosis (typical or atypical) and MECP2 variant severity did not differ
between the first and second iteration.

Results
Frequency of anxiety‑like behavior

During the second iteration of the RNHS, data were
obtained specifically asking parents to report how
often their child was anxious or nervous. A majority of
participants (77.5%) were reported to be at least occasionally anxious/nervous, with 24.1% being reported
as anxious/nervous frequently, very frequently, or constantly (Fig. 2). Frequency of being anxious or nervous
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Table 1 Baseline clinical characteristics of participants from the Rett syndrome natural history study (RNHS) analyzed in this study
Characteristic

Category

Race1**

White

88%

92%

Black or African American

7%

5%

American Indian or Alaska Native

3%

1%

Asian

5%

5%

Native Hawaiian or Pacific Islander

(Not assessed)

1%

Not Hispanic, Latino, or Spanish Origin

85%

87%

Hispanic, Latino, or Spanish Origin

15%

11%

Classic (typical)

87%

89%

Variant (atypical)

13%

11%

Mild

32.5%

35.0%

Moderate

16.7%

17.0%

Severe

50.8%

47.9%

9.1 years ± 8.8 (range 1–66)

15.2 years ± 10.7 (range 1–58)

Ethnicity*
RTT diagnosis
MECP2 severity

Age***
CSS total***

MECP2 severity

Second iteration (n = 662)

22.2 ± 7.8

MBA total**
RTT diagnosis

First iteration (n = 1070)

46.9 ± 15.0

Cohort 1 (n = 718)

23.8 ± 8.3

48.8 ± 13.8

Both studiesa (n = 352)

Cohort 2 (n = 310)

Classic (typical)

83.4%

93.5%***

Variant (atypical)

16.6%

6.5%***

16.8%

Mild

32.4%

32.7%

37.7%

Moderate

16.4%

17.1%

17.0%

Severe

51.1%

50.1%

45.3%

9.22 ± 8.6 (range 1–66)

8.84 ± 9.1 (range 1–48)

12.56 ± 10.7*** (range 1–52)

49.01 ± 15.2

42.64 ± 13.6***

47.84 ± 14.5

Age
CSS total
MBA total

22.92 ± 7.9

20.79 ± 7.4***

83.2%

22.18 ± 8.4

Both Subjects participating in both the first and second iteration, Cohort 1 Subjects only participating in the first iteration, Cohort 2 Subjects only participating in the
second iteration, CSS Clinical Severity Scale, First iteration Subjects enrolled 2006–2015, MBA Motor Behavioral Assessment, Mild MECP2 severity R133C, R294X, R306C,
and C-terminal truncations, Moderate MECP2 severity T158M and other point mutations, RTTRett syndrome, Severe MECP2 severity R106W, R168X, R255X, R270X, early
truncations, large deletions, and splice site, Second iteration Subjects enrolled 2015–2019
1

More than one option could be selected so total > 100%; ***P < 0.001, **P < 0.01, *P < 0.05 compared to first iteration or cohort 1

a

Baseline data from first iteration

Fig. 2 Responses to: How often is your child anxious or nervous? From 662 participants in the second iteration of the RNHS. First iteration =
subjects enrolled 2006–2015; second iteration = subjects enrolled 2015–2019

was not different based on type of RTT diagnosis (typical or atypical, P = 0.171) or whether participants were
enrolled in both iterations or only in the second (P =
0.406). Frequency of being anxious showed no correlation with age or clinical severity based on MBA total

score. Increased frequency of anxious behavior correlated with lower severity based on CSS total score,
but the magnitude of the association was negligible
(Spearman’s rho = − 0.151, P < 0.01). Participants with
mild MECP2 variants had higher frequency of anxious
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behavior than participants with more severe variants (P
< 0.001).
Severity of anxiety‑like behavior

Severity was assessed in the second iteration through
parental report of anxious/nervous behavior as a major
concern and through direct parental report of treatment. Specifically, the second iteration of the RNHS
asked parents to select “the three biggest problems”
affecting their child’s quality of life in the past six
months from a list including both behavioral and medical complications of RTT: anxiety was the greatest concern for 2.6% and was within the top 3 concerns for 10%
of participants (data not shown). Parents also reported
whether their child displayed certain problem moods
or behaviors, and whether those required treatment.
Being anxious/nervous was the most common behavioral problem reported and treated, with a majority
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of those reporting good control of symptoms with
treatment (Table 2). The frequency of anxious/nervous behavior was greater in those participants reporting treatment and in those with reported poor control
(Fig. 3). Participants treated for anxiety by direct parental report were older than those without treatment (P
< 0.001). In addition, participants with good control of
anxious/nervous behavior were also older than those
with poor control or no treatment (P < 0.001). Parental report of treatment frequency differed by MECP2
variant severity (P < 0.001); participants with mild variants were more than twice as likely as participants with
severe variants to report treatment for being anxious or
nervous (23.5% vs 10.1%). The percent of participants
reporting treatment for being anxious did not differ
based on RTT diagnosis type (typical or atypical) (P =
0.795), study enrollment (both or second iteration only,

Table 2 Rett syndrome natural history study (RNHS) participants’ direct report of treatment for behavioral problems (n = 655)
Is your child treated for:

No

Yes, my child is treated for this and it is
well controlled

Yes, my child is treated
for this but it is poorly
controlled

Being anxious or nervous

83.4%

11.9%

4.7%

Being sad, miserable, or uncomfortable

87.8%

8.1%

4.1%

Rapid changes in mood

91.0%

6.1%

2.9%

Being irritable

91.8%

5.5%

2.7%

Screaming episodes

93.4%

4.1%

2.4%

Self-abusive behaviors

95.9%

2.9%

1.2%

Being aggressive and abusive to others

96.6%

2.1%

1.2%

Being excessively active

98.5%

1.1%

0.5%

Having a low level of activity

99.2%

0.3%

0.5%

Fig. 3 Frequency of anxious/nervous behavior based on direct report of anxiolytic treatment. Frequency values: 0 = “never”, 1 = “occasionally”, 2 =
“frequently”, 3 = “very frequently”, 4 = “constantly”
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P = 0.356), or clinical severity based on CSS or MBA
total scores (P = 0.186, P = 0.993).
Frequency of anxiolytic use by medication logs

Review of medication logs found “anxiety” noted as an
indication for a similar number of participants in both
iterations of the RNHS: 15.0% of participants in the first
and 14.5% in the second (P = 0.835). The most commonly
used drugs were escitalopram, sertraline, fluoxetine, and
buspirone. Anxiolytic treatment according to medication
log entries did not vary by type of RTT diagnosis (typical
or atypical) (P = 0.759). Participants on a medication for
the indication of anxiety were older than their untreated

Page 7 of 11

counterparts (Table 3, Fig. 4). The proportion of participants on anxiolytic treatment was higher for participants
over 18 years of age (21.3%) than for pediatric participants (12.9%; P < 0.001). Anxiolytic treatment was higher
at younger ages in the first iteration than in the second
iteration (Fig. 4). In the first iteration, anxiolytic use by
medication log was also associated with lower clinical
severity, but this was not replicated in the second iteration (Table 3). Similar to direct parental report, medication logs reported more anxiolytic use in participants
with mild MECP2 variants than severe variants in both
first (20.1% vs. 10.9%, P = 0.001) and second (18.6% vs.
10.6%, P = 0.034; Fig. 5) iterations.

Table 3 Clinical features of participants based on treatment recorded in medication logs
Study

Feature

Any anxiolytic
Yes

First iteration (n= 1068)

Age (years)
CSS total score
MBA total score

Second iteration (n= 662)

Age (years)
CSS total score
MBA total score

11.3 ± 9.7

19.9 ± 7.1

44.0 ± 14.1

18.7 ± 10.6

24.0 ± 7.1

49.7 ±13.7

SSRI
No
8.7 ± 8.6

22.6 ± 7.8

47.4 ± 15.1

14.6 ± 10.6

23.8 ± 8.5

48.6 ± 13.8

Significance
P < 0.000*
P < 0.000*
P = 0.006*

P < 0.000*
P = 0.790

P = 0.487

Yes
11.3 ± 9.8

18.9 ± 6.9

43.8 ± 14.0

20.2 ± 10.6

23.0 ± 7.2

48.3 ± 10.7

No
8.76 ± 8.6

22.7 ± 7.8

47.4 ± 15.1

14.5 ± 10.5

23.9 ± 8.4

48.8 ± 14.1

Significance
P < 0.000*
P < 0.000*
P = 0.006*

P < 0.000*
P = 0.324

P = 0.710

Values are reported as mean ± standard deviation

CSS Clinical Severity Scale, First iteration Subjects enrolled 2006–2015, MBA Motor Behavioral Assessment, Second iteration Subjects enrolled 2015–2019
*P statistically significant

Fig. 4 Frequency of anxiolytic use reported in medication logs by age group. First iteration = subjects enrolled 2006–2015; second iteration =
subjects enrolled 2015–2019
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Fig. 5 Frequency of anxiolytic use reported in medication logs by MECP2 pathogenic variant. MECP2 variant percent in parentheses indicates
overall frequency of the variant in the entire study population. †Severe variant = R106W, R168X, R255X, R270X, early truncations, large deletions,
and splice site. First iteration = subjects enrolled 2006–2015; second iteration = subjects enrolled 2015–2019

Frequency of SSRI use by medication logs

Based on medication logs, SSRI use for any indication
was reported for 13.1% of participants in the first iteration and 11.0% in the second iteration (P = 0.414). The
indication for use of an SSRI in the second iteration was
primarily anxiety (87%) and clinical findings were similar
to the anxiolytic treatment group defined by medication
logs. SSRI use was similar between participants with typical and atypical RTT (P = 0.383). SSRI use was associated
with older age in both iterations of the RNHS, and with
lower clinical severity in the first iteration (Table 3). SSRI
use was more common in participants with mild than
severe MECP2 variants in the first (20.4% vs. 8.1%, P <
0.001) and second (15.9% vs. 8.0%, P = 0.018) iterations.
Comparison of direct report and medication logs

Looking only at individuals in both studies (n = 352), the
number of participants receiving anxiolytic treatment is
similar whether the data were collected from medication
logs in the first iteration (18.8%) or from direct report in
the second iteration (18.5%; P < 0.000). In all participants
in the second iteration (n = 662), anxiolytic treatment
according to the medication log and to the direct report do
not overlap perfectly (14.5% and 16.6%, respectively), but
their relationship is significant (P < 0.001); this significance
holds for participants either in both studies (n = 350, P <
0.001) or only in cohort 2 (n = 305, P < 0.001). The frequency of anxious/nervous behavior was directly related

to anxiolytic treatment based on direct report and medication log report of anxiolytic or SSRI use (all P < 0.001).

Discussion
Individuals with RTT display a wide variety of neurologic
problems. Although the initial descriptions of the disorder highlighted autistic features, the current view is that
other behavioral abnormalities are more significant and
occur throughout the life of the individual. While several
studies have reported on anxiety in RTT, these investigations have involved small numbers of participants and in
general have not focused on this specific behavioral problem. The present study intended to provide the first largescale examination of anxiety in RTT, utilizing the data
collected by the multi-site RNHS. Because of the lack of
records on psychiatric diagnoses in this study, we used
a combination of parental report and medication logs
from 1380 participants in two iterations of the RNHS.
We confirmed the relatively high frequency of anxious or
nervous behavior in RTT, which reached a level of clinical concern in at least 15% of participants as indicated by
medication logs. We also identified frequency of anxietylike behaviors, older age, and mild MECP2 variants as
predictors of or associated factors to anxiolytic and SSRI
use in RTT. Although it was reported that pharmacological treatment achieved good control of anxiety in most
participants, this behavioral problem represented a major
concern for approximately 10% of caregivers.
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Previous attempts to quantify anxiety-like behavior in RTT have relied on rating scales administered to
parents/caregivers or clinicians. The Rett Syndrome
Behaviour Questionnaire (RSBQ) is a parent/caregiver
scale addressing problem behaviors in RTT, with a fear/
anxiety subscale consisting of 4 items. Anderson et al.
[1] reviewed the RSBQ scores of an Australian cohort of
individuals with RTT (n = 137) and found that anxiety
occurred “often” in 11% of participants and “occasionally” in 58%. This study similarly shows that a majority of
participants’ parents consider them to be at least occasionally anxious or nervous, with a minority having more
frequent anxiety-like behavior.
Taking into consideration the challenges in identifying and quantifying anxiety-like behaviors in RTT, we
combined two sources of information to determine the
frequency and severity of anxiety-like behaviors and
their associated features in this population. Data from
medication logs in the first iteration and direct reports
in the second iteration were comparable, as was anxiolytic treatment according to medication logs between
the first and second iterations. Data consistency was
supported by comparing findings from participants in
both studies with those only in cohort 2. As suggested
by previous studies [1, 8, 19, 27], our analyses demonstrated a relatively high frequency of anxiety-like
behaviors in RTT. The figure (~ 15%) is higher than that
reported in the general pediatric population (~ 6.5%
worldwide) [24]. However, compared to other neurodevelopmental disorders, anxiety in RTT is less common:
~ 80% in fragile X syndrome [10] and ~ 25% in autism
spectrum disorder [26].
We evaluated severity of anxiety-like behaviors in RTT
using a combination of measures, including parental
selection of the most troublesome medical and behavioral issues affecting their child’s quality of life, behavioral
problems requiring treatment, and the level of symptom control with treatment. Anxiety was one of the top
quality of life concerns for a substantial proportion of
participants (10%) and was the most common behavioral problem reported and treated, with reasonable control achieved in most cases (approximately two-thirds).
To our knowledge, only one study has examined anxiety severity in RTT. A cohort of girls with RTT (n = 74)
had moderate severity scores using the RSBQ and two
other parent/caregiver scales that measure anxiety-like
behavior in intellectual disability and autism spectrum
disorder: the Anxiety, Depression, and Mood Scale
(ADAMS) and the Aberrant Behavior Checklist–Community (ABC-C) [3]. This study also found that anxiety
scores were inversely related to clinical severity and quality of life scores. In general terms, our study confirms
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the association between more severe anxiety and milder
clinical severity. Both RNHS iterations demonstrated
higher frequency and severity of anxiety-like behaviors
in participants with milder MECP2 pathogenic variants
(R133C, R294X, R306C, and C-terminal truncations).
However, the inverse relationship between anxiety scores
and clinical severity was only present in the first iteration
of the RNHS; it is unclear why this did not hold true in
the second iteration.
In the RNHS, approximately 15% of participants used
medications for anxiety. The present study was not
designed to assess the efficacy or safety of these medications, but parent report indicates that most treated
participants have good control. Associated factors to
anxiolytic medication use in general, and SSRI use in
particular, included increased frequency of anxietylike behaviors, older age, and mild MECP2 variants.
Increased treatment in older individuals may indicate
greater impact of anxiety on functioning at older ages,
greater clinician comfort with prescribing these medications in an older population, or both. Interestingly, RTT
diagnosis type (typical or atypical) was not related to frequency or severity of anxiety-like behaviors.
This study is based on a large cohort of 1380 females with
RTT, with 352 participating in both iterations of the RNHS,
studied over many years. Therefore, the results are likely
to be generalizable to the broad RTT community. Males
and individuals with RTT-like disorders were excluded
from the analyses, so results presented here may not apply
to these populations. In addition to children, we included
information collected from adult participants in this study.
However, older individuals in neurodevelopmental disorder research studies may be a non-representative group
because of ascertainment bias (due to severity, caregiver
motivation, or other factors). Clear limitations in this study
include the lack of standardized questionnaires and objective measures of anxiety-like behaviors. In a phase 1 clinical trial of IGF-1 in RTT, improved right-sided alpha band
asymmetry on electroencephalogram (EEG), a biomarker
of anxiety and mood disorders, was mildly associated with
lowered ADAMS scores in 5 out of 6 participants [16].
These data support the notion that anxiety-like phenomena
are a component of RTT; however, adequate instruments
for assessing anxiety in RTT are still lacking. The complex
study design with a partially overlapping cohort added
analytical challenges and limited the conclusions. Consequently, future anxiety research in RTT should focus on
developing standardized clinical measures, such as questionnaires, and identifying biomarkers of relevance to this
abnormal behavior. Follow-up studies should integrate clinical data, as the one analyzed here, with novel and already
established biomarkers of anxiety in the general population
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(e.g., electrodermal activity, heart rate variability, cortisol,
catecholamines). Complementing this, efficacy and safety
of specific SSRIs and other anxiolytics should be carefully
documented in the RTT population. Non-pharmacological
treatments of anxiety should also be considered and evaluated in RTT. Ultimately, future studies should be focused
on supporting improvements in the clinical care of anxiety
in RTT, including the accuracy of diagnosis and effectiveness of treatment.

Conclusions
This analysis demonstrates that most individuals with RTT
display, at least occasionally, anxiety-like behavior and that
anxiety is a significant parental concern. Older individuals
and those with milder MECP2 variants are more likely to be
treated, and pharmacological treatment can improve symptoms. Better diagnosis and treatment of anxiety in RTT
should be a goal of both future studies and clinical care.
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